“Dipan Mehta is positive on Aurobindo Pharma, viewing recent Form 483 observations as not a major concern due to diversified manufacturing. He sees the broader pharma sector as a safe bet in volatile times, supported by tailwinds like rupee depreciation, opportunities in weight-loss drugs, and improved capital allocation.”

Dipan Mehta’s track record: 12 graded calls · 95% CI 25–75%